Biohaven Financial Results
Biohaven Ltd. reported third quarter 2026 financial results and provided updates on its clinical pipeline, including the FDA's acceptance of the NDA resubmission for troriluzole. The company highlighted significant regional licensing deals with SK Biopharmaceuticals and Ono Pharmaceutical, which are expected to provide substantial near-term cash consideration.
“This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value. We are excited to have entered into the first ever regional collaboration for an extracellular protein degrader with Ono Pharmaceutical to develop and commercialize our MoDE IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan and the ASEAN region.”
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
“Establishing these unique collaborations with two leading global drug development and commercialization companies is a testament to the impressive potential and versatility of our portfolio.”
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven